Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
Cardiovasc Hematol Disord Drug Targets
; 21(2): 88-90, 2021.
Article
in English
| MEDLINE | ID: covidwho-1357470
ABSTRACT
After the outbreak of COVID-19, many novel drugs have been introduced to improve patients' conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pyrazines
/
Adenosine Monophosphate
/
Alanine
/
Amides
/
COVID-19 Drug Treatment
/
Heart Diseases
Limits:
Humans
Language:
English
Journal:
Cardiovasc Hematol Disord Drug Targets
Journal subject:
Vascular Diseases
/
Cardiology
/
Hematology
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
1871529X21666210812103535
Similar
MEDLINE
...
LILACS
LIS